Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus

Systemic Lupus Erythematosus

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Autoimmun Rev.

Parodis I, Sjöwall C, Jönsen A, Ramsköld D, Zickert A, Frodlund M, Sohrabian A, Arnaud L, Rönnelid J, Malmström V, Bengtsson AA, Gunnarsson I

doi: 10.1016/j.autrev.2017.02.005.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

doi: 10.1136/annrheumdis-2018-214427.

Systemic Lupus Erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

Arthritis Res Ther.

Sohrabian A, Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, Sjöwall C, Bengtsson AA, Gunnarsson I, Rönnelid J

doi: 10.1186/s13075-019-2056-y.

Systemic Lupus Erythematosus

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Arthritis Res Ther.

Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D

doi: 10.1186/s13075-020-02177-0.

Systemic Lupus Erythematosus

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

J Rheumatol.

Quevedo-Abeledo JC, Rúa-Figueroa Í, Sánchez-Pérez H, Tejera-Segura B, de Vera-González A, González-Delgado A, Llorca J, González-Gay MÁ, Ferraz-Amaro I

doi: 10.3899/jrheum.180881.

Systemic Lupus Erythematosus

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

Ann Rheum Dis.

Reid S, Alexsson A, Frodlund M, Morris D, Sandling JK, Bolin K, Svenungsson E, Jönsen A, Bengtsson C, Gunnarsson I, Illescas Rodriguez V, Bengtsson A, Arve S, Rantapää-Dahlqvist S, Eloranta ML, Syvänen AC, Sjöwall C, Vyse TJ, Rönnblom L, Leonard D

doi: 10.1136/annrheumdis-2019-216227.

Systemic Lupus Erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

J Rheumatol

Kim JW, Jung JY, Kim HA, Yang JI, Kwak DW, Suh CH

doi: 10.3899/jrheum.200802

Systemic Lupus Erythematosus

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus

Lupus.

Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B

doi: 10.1177/0961203316655215

Systemic Lupus Erythematosus

Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI)

Arthritis Rheumatol.

Legge A, Kirkland S, Rockwood K, Andreou P, Bae SC, Gordon C, Romero-Diaz J, Sanchez-Guerrero J, Wallace DJ, Bernatsky S, Clarke AE, Merrill JT, Ginzler EM, Fortin PR, Gladman DD, Urowitz MB, Bruce IN, Isenberg DA, Rahman A, Alarcón GS, Petri M, Khamashta MA, Dooley MA, Ramsey-Goldman R, Manzi S, Zoma AA, Aranow C, Mackay M, Ruiz-Irastorza G, Lim SS, Inanc M, van Vollenhoven RF, Jonsen A, Nived O, Ramos-Casals M, Kamen DL, Kalunian KC, Jacobsen S, Peschken CA, Askanase A, Hanly JG

doi: 10.1002/art.41144.

Related content

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus

Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis

Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus

Lupus Low Disease Activity State achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus

Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus

Prediction of damage accrual in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI)